Clinical trials
Onchocerciasis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 4 |
| Not yet recruiting | 3 |
| Active, not recruiting | 3 |
| Terminated | 2 |
| Unknown status | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Medicines Development for Global Health | 5 |
| Washington University School of Medicine | 5 |
| Universiteit Antwerpen | 3 |
| Drugs for Neglected Diseases | 2 |
| Liverpool School of Tropical Medicine | 2 |
| Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 2 |
| University Hospitals Cleveland Medical Center | 2 |
| AbbVie | 1 |
| Bayer | 1 |
| Bioaster | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Onchocerciasis | 35 |
| Filariasis | 8 |
| Onchocerciasis, Ocular | 8 |
| Elephantiasis, Filarial | 7 |
| Neglected Diseases | 7 |
| Epilepsy | 5 |
| Loiasis | 4 |
| Parasitic Diseases | 4 |
| Helminthiasis | 3 |
| Infections | 3 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.